Previous 10 | Next 10 |
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”) announced today that, due to the public health impact of the coronavirus pandemic, the location of the Company’s 2020 annual meeting of stockholders has been changed and will be held in a virtual me...
MARINA DEL REY, Calif. , March 30, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that, following a v...
Submission supported by pivotal CAPTAIN study demonstrating statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta At least 30% of asthma patients continue to experience symptoms even when adherent to ICS/LABA treatment GlaxoSmit...
The Food and Drug Administration is asking one of its panels of outside experts to help it make a decision about GlaxoSmithKline 's (NYSE: GSK) request to add data to the label of Trelegy Ellipta, its chronic obstructive pulmonary disease (COPD) drug. The pulmonary-allergy drugs advisory comm...
Since publishing my bullish piece on Innoviva Inc. ( INVA ), the shares are up just under 14%, against a gain of 7% for the S&P 500 over the same time period. While this is gratifying on some level, I think a stock that was trading at $12.70 is by definition much less risky than one that...
Total net revenue decreased by 4.9% to $76.0 million in the fourth quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased by 3.9% to $70.3 million in the fourth quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. (NASDAQ: INV...
Armata Pharmaceuticals (NYSEMKT: ARMP ) and Innoviva (NASDAQ: INVA ) have entered into a securities purchase agreement pursuant to which Innoviva will purchase ~$25M in Armata common stock and warrant securities. More news on: Armata Pharmaceuticals, Inc., Innoviva, Inc., Healthcare stoc...
MARINA DEL REY , Calif. and BRISBANE, Calif. , Jan. 28, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (...
Drug developer Theravance Biopharma (NASDAQ: TBPH) is not your typical biotech company. It emerged in 2014 from a spinoff of the R&D branch of its parent company, now called Innoviva (NASDAQ: INVA) . Shareholders in Innoviva received a dividend of Theravance Biopharma stock. The R&am...
The markets have been performing very well in 2019 with the Dow Jones, the Nasdaq, and the S&P 500 all up more than 20% since the beginning of the year. That's great news for investors who are already holding stocks, but for those looking to get into the market for the first time, it means c...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...